Amanda Medley, APRN
Psychiatric/Mental Health · Elizabethtown, KYNPI 1538620356
Payments from drug & device makers
Across 780 payments — averaging $17.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$5K
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$939
- Corium, LLC$933
- Vanda Pharmaceuticals Inc.$878
- Lundbeck LLC$813
- plus $4K from 21 others
What the payments were for
- Speaking & faculty fees$1,65012%
- Travel & lodging$1,2409%
- Food & beverage$11,05279%
- Education$660%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 119 | $4,807 |
| AbbVie | 113 | $1,214 |
| Otsuka America Pharmaceutical, Inc. | 62 | $939 |
| Corium, LLC | 80 | $933 |
| Vanda Pharmaceuticals Inc. | 33 | $878 |
| Lundbeck LLC | 94 | $813 |
| Teva Pharmaceuticals USA, Inc. | 41 | $803 |
| Alkermes, Inc. | 53 | $797 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 46 | $619 |
| Takeda Pharmaceuticals U.S.A., Inc. | 28 | $364 |
| Sunovion Pharmaceuticals Inc. | 21 | $322 |
| Axsome Therapeutics, Inc. | 14 | $215 |
| Johnson & Johnson | 12 | $201 |
| E.r. Squibb & Sons, L.L.C. | 11 | $162 |
| Indivior Inc. | 9 | $159 |
| Neurocrine Biosciences, Inc. | 8 | $158 |
| Ironshore Pharmaceuticals Inc. | 7 | $112 |
| Noven Therapeutics, LLC | 6 | $97 |
| USWM, LLC | 5 | $93 |
| Tris Pharma Inc | 6 | $90 |
| Biogen | 4 | $80 |
| Idorsia Pharmaceuticals US Inc | 3 | $52 |
| Neuronetics, Inc. | 1 | $29 |
| Bausch Health US, LLC | 1 | $24 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $16 |
| Gilead | 1 | $16 |
| Bioventus LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,007 in reported general payments places this provider in the 95th percentile of 946 psychiatric/mental health providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 113 | $161,004 |
| Abilify MaintenaAripiprazole | 42 | $113,825 |
| RexultiBrexpiprazole | 40 | $65,708 |
| Invega SustennaPaliperidone Palmitate | 11 | $24,900 |
| TrintellixVortioxetine Hydrobromide | 33 | $21,306 |
| Paliperidone ErPaliperidone | 34 | $12,081 |
| FetzimaLevomilnacipran Hcl | 11 | $7,388 |
| Lurasidone Hcl | 18 | $5,854 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 63 | $4,946 |
| Dexmethylphenidate Hcl ErDexmethylphenidate Hcl | 12 | $4,381 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 63 | $4,335 |
| Prazosin Hcl | 63 | $2,701 |
| Buspirone Hcl | 138 | $2,451 |
| Doxepin Hcl | 108 | $2,424 |
| Quetiapine Fumarate | 130 | $1,834 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $939 | $179,53382 claims |
| AbbVieVraylar, Fetzima | $1,214 | $168,392124 claims |
| Johnson & JohnsonInvega Sustenna | $201 | $24,90011 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $364 | $21,30633 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 946 psychiatric/mental health providers in Kentucky.
Other psychiatric/mental health in Elizabethtown
- Jason DunnElizabethtown$11K
- Donald BlackburnElizabethtown$8K
- Sandra AubreyElizabethtown$7K
- Cheri FrederickElizabethtown$7K
- Theresa WattsAshland$645K
- Rachel ColeHopkinsville$503K
- Denise de AngelisLouisville$384K
- Jennifer SampangCrestview Hills$322K
- Jeremy FisherSouth Shore$197K
- Jessica EstesLewisport$175K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.